Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Liposomal Cytarabine Induces Less Neurocognitive Dysfunction Than Intrathecal Methotrexate in an Animal Model

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Meropenem to Children With Febrile Neutropenia Induces Monoresistant Pseudomonas aeruginosa

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Improved Survival of Children, Adolescents, and Young Adults With Head and Neck Soft Tissue Sarcomas in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Hepatotoxicity During Maintenance Therapy and Prognosis in Children With Acute Lymphoblastic Leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Asparaginase Enzyme Activity Levels and Toxicity in Childhood Acute Lymphoblastic Leukemia: a NOPHO ALL2008 study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Increments in DNA-thioguanine level during thiopurine enhanced maintenance therapy of acute lymphoblastic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Liposomal cytarabine is currently being tested clinically as an alternative to intrathecal (IT) methotrexate (MTX) for preventing relapse within the central nervous system among patients with acute lymphoblastic leukemia. To compare the toxicity and cognitive deficits caused by IT MTX versus liposomal cytarabine, juvenile Long Evans rats were treated with IT injections of MTX 1 mg/kg×4 doses over 8 days, or liposomal cytarabine 0.8 mg once. Mean concentrations of free cytarabine in cerebrospinal fluid remained above the cytotoxic threshold of 0.4 μM for 2 weeks after dosing. Animals treated with liposomal cytarabine exhibited normal recognition and spatial memory 4 weeks after injection. In contrast, exposure to IT MTX led to impaired cognitive function. In addition, mean hematocrit on day 11 was significantly lower in the MTX-treated animals (30.8%; 95% confidence interval, 27.0%-34.7%; n=6) compared with that in the liposomal cytarabine-treated animals (39.5%; 95% confidence interval, 38.4%-40.6%; n=6; P<0.0001). Our data suggest that liposomal cytarabine induces fewer neurocognitive deficits and less acute hematologic toxicity compared with IT MTX. Liposomal cytarabine may therefore have therapeutic advantages over IT MTX, if it is equally effective in preventing relapse.

Original languageEnglish
JournalJournal of Pediatric Hematology / Oncology
Volume40
Issue number2
Pages (from-to)e91-e96
ISSN1077-4114
DOIs
Publication statusPublished - Mar 2018

    Research areas

  • Journal Article

ID: 52773112